thalidomide has been researched along with Acquired Immune Deficiency Syndrome in 60 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 9.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "Thalidomide, which inhibits monocyte tumor necrosis factor (TNF)-alpha production and costimulates T cells, was tested for immune modulation in patients with human immunodeficiency virus (HIV) infection and tuberculosis (TB) in a placebo-controlled study." | 9.09 | Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. ( Bekker, LG; Haslett, P; Kaplan, G; Maartens, G; Steyn, L, 2000) |
| "A patient with AIDS was diagnosed with inflammatory pseudotumor with small bowel involvement." | 5.31 | Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: clinical improvement after initiation of thalidomide treatment. ( Aboulafia, DM, 2000) |
| "A multicenter, double-blind, randomized, placebo-controlled clinical trial was conducted to determine the safety and efficacy of thalidomide for treating esophageal aphthous ulceration in persons infected with human immunodeficiency virus (HIV)." | 5.09 | Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. ( Basgoz, N; Chernoff, M; Fahey, JL; Fox, L; Hooton, TM; Jackson, JB; Jacobson, JM; MacPhail, LA; Sha, BE; Shikuma, CM; Simpson, DM; Spritzler, J; Trapnell, CB; Wohl, DA; Wu, AW, 1999) |
| "Thalidomide, which inhibits monocyte tumor necrosis factor (TNF)-alpha production and costimulates T cells, was tested for immune modulation in patients with human immunodeficiency virus (HIV) infection and tuberculosis (TB) in a placebo-controlled study." | 5.09 | Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. ( Bekker, LG; Haslett, P; Kaplan, G; Maartens, G; Steyn, L, 2000) |
| "Eighteen subjects with chronic diarrhea caused by Enterocytozoon bieneusi that had not responded symptomatically to albendazole and 1 untreated subject with Encephalitozoon intestinalis received 1 month of thalidomide, 100 mg nocte." | 5.08 | Thalidomide: a novel therapy for microsporidiosis. ( Barrett, M; Ellis, D; Francis, N; Gazzard, B; Rowbottom, A; Sharpstone, D; Tovey, G, 1997) |
| "Thalidomide is being tested as an anti-HIV drug, a weight loss treatment, an immune system regulator, a tuberculosis treatment supplement, and a treatment for microsporidiosis." | 3.69 | Treatment for weight loss, tuberculosis and AIDS? ( , 1995) |
| "In a series of 12 patients suffering from an HIV infection, including 9 with confirmed AIDS, who complained about pharyngeal pain in a fixed site, having a progressive intensity and not relieved by antalgics and the specific treatments that were prescribed empirically, and for whom etiological investigation yielded negative results, Thalidomide proved to be the only effective means of healing the exulcerated, nail-mark lesions or the ulcerated, budding, neoplastic-like lesions, and of completely suppressing pain." | 3.68 | [Mouth and pharyngeal hyperalgesic syndromes in AIDS]. ( Barry, B; Depondt, J; Gehanno, P; Gorin, I; Guedon, C; Leport, C; Poignonec, S, 1990) |
| "Oral thalidomide was tolerated in this population at doses up to 1,000 mg/d for as long as 12 months and was found to induce clinically meaningful anti-KS responses in a sizable subset of the patients." | 2.69 | Activity of thalidomide in AIDS-related Kaposi's sarcoma. ( Feigal, E; Figg, WD; Goedert, JJ; Little, RF; Marshall, V; Newcomb, FM; Pluda, JM; Steinberg, SM; Tosato, G; Welles, L; Whitby, D; Wyvill, KM; Yarchoan, R, 2000) |
| "Thalidomide treatment increased HIV RNA levels (median increase, 0." | 2.68 | Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Jackson, JB; Jacobson, JM; Ketter, N; MacPhail, LA; Spritzler, J; Vasquez, GJ; Wohl, DA; Wu, AW, 1997) |
| " The Food and Drug Administration (FDA), Celgene, and AIDS activists eliminated the randomized dose portion of the program to allow physicians to determine the dosage to use." | 2.68 | Thalidomide's elusive access. ( Gilden, D, 1995) |
| "Management of relapsing or refractory immune reconstitution inflammatory syndromes (IRISs) despite corticosteroid therapy is yet to be defined." | 1.38 | Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. ( Brunel, AS; Le Moing, V; Lortholary, O; Makinson, A; Montes, B; Reynes, J; Rubbo, PA; Tuaillon, E, 2012) |
| "A patient with AIDS was diagnosed with inflammatory pseudotumor with small bowel involvement." | 1.31 | Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: clinical improvement after initiation of thalidomide treatment. ( Aboulafia, DM, 2000) |
| "Of the 94 patients 50% had an AIDS diagnosis." | 1.30 | Severe oral ulceration in patients with HIV infection: a case series. ( Robinson, P; Williams, IG; Zakrzewska, JM, 1997) |
| "Thalidomide may cause birth defects, and larger doses can cause neuropathy or other adverse effects." | 1.29 | Wasting syndrome--affordable treatments. ( James, JS, 1995) |
| "Thalidomide appears to be an effective agent for the treatment of severe RAS unresponsive to traditional therapies." | 1.28 | Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. ( Nicolau, DP; West, TE, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 48 (80.00) | 18.2507 |
| 2000's | 8 (13.33) | 29.6817 |
| 2010's | 4 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, NK | 1 |
| Wang, CC | 1 |
| Mannis, GN | 1 |
| Yu, JJ | 1 |
| Rubenstein, JL | 1 |
| Dauby, N | 1 |
| Coussement, J | 1 |
| Karakike, E | 1 |
| Ungureanu, C | 1 |
| De Wit, S | 1 |
| Payen, MC | 1 |
| Martinez, V | 1 |
| Tateo, M | 1 |
| Castilla, MA | 1 |
| Melica, G | 1 |
| Kirstetter, M | 1 |
| Boué, F | 1 |
| Brunel, AS | 1 |
| Reynes, J | 1 |
| Tuaillon, E | 1 |
| Rubbo, PA | 1 |
| Lortholary, O | 1 |
| Montes, B | 1 |
| Le Moing, V | 1 |
| Makinson, A | 1 |
| Daemmrich, A | 1 |
| Krucken, G | 1 |
| Onda, J | 1 |
| Oka, S | 1 |
| Thompson, C | 1 |
| Gershon, D | 1 |
| Berger, TG | 1 |
| Hoffman, C | 1 |
| Thieberg, MD | 1 |
| Weinroth, SE | 1 |
| Parenti, DM | 1 |
| Simon, GL | 1 |
| Sire, S | 1 |
| Fraisse, P | 1 |
| Rey, D | 1 |
| Jacquemin, C | 1 |
| Kempf, G | 1 |
| Partisani, M | 1 |
| Lang, JM | 1 |
| Naum, SM | 1 |
| Molloy, PJ | 1 |
| Kania, RJ | 1 |
| McGarr, J | 1 |
| Van Thiel, DH | 1 |
| D'Arcy, PF | 1 |
| Griffin, JP | 1 |
| Makonkawkeyoon, S | 1 |
| Limson-Pobre, RN | 1 |
| Moreira, AL | 1 |
| Schauf, V | 1 |
| Kaplan, G | 2 |
| Ghigliotti, G | 1 |
| Repetto, T | 1 |
| Farris, A | 1 |
| Roy, MT | 1 |
| De Marchi, R | 1 |
| Couderc, LJ | 1 |
| Balloul, E | 1 |
| Caubarrere, I | 1 |
| Domingo, P | 1 |
| Ris, J | 1 |
| López-Contreras, J | 1 |
| Bellomo, A | 1 |
| Schorr-Lesnick, B | 1 |
| Jacobson, JM | 2 |
| Greenspan, JS | 1 |
| Spritzler, J | 2 |
| Ketter, N | 1 |
| Fahey, JL | 2 |
| Jackson, JB | 2 |
| Fox, L | 2 |
| Chernoff, M | 2 |
| Wu, AW | 2 |
| MacPhail, LA | 2 |
| Vasquez, GJ | 1 |
| Wohl, DA | 2 |
| Sharpstone, D | 1 |
| Rowbottom, A | 1 |
| Francis, N | 1 |
| Tovey, G | 1 |
| Ellis, D | 1 |
| Barrett, M | 1 |
| Gazzard, B | 2 |
| Saphir, A | 1 |
| Zakrzewska, JM | 1 |
| Robinson, P | 1 |
| Williams, IG | 1 |
| Jibaly, RM | 1 |
| Moallem, H | 1 |
| Fikrig, SM | 1 |
| Rabinowitz, SS | 1 |
| Herranz, P | 1 |
| Pizarro, A | 1 |
| De Lucas, R | 1 |
| Arribas, JR | 1 |
| García-Tobaruela, A | 1 |
| Peña, JM | 1 |
| Casado, M | 1 |
| Hooton, TM | 1 |
| Sha, BE | 1 |
| Shikuma, CM | 1 |
| Simpson, DM | 1 |
| Trapnell, CB | 1 |
| Basgoz, N | 1 |
| Marriott, JB | 1 |
| Muller, G | 1 |
| Dalgleish, AG | 1 |
| Diz Dios, P | 1 |
| Sopeña, B | 1 |
| Cameselle, J | 1 |
| Butrón, M | 1 |
| Crespo, M | 1 |
| Ocampo, A | 1 |
| Bekker, LG | 1 |
| Haslett, P | 1 |
| Maartens, G | 1 |
| Steyn, L | 1 |
| Aboulafia, DM | 1 |
| Little, RF | 1 |
| Wyvill, KM | 1 |
| Pluda, JM | 1 |
| Welles, L | 1 |
| Marshall, V | 1 |
| Figg, WD | 1 |
| Newcomb, FM | 1 |
| Tosato, G | 1 |
| Feigal, E | 1 |
| Steinberg, SM | 1 |
| Whitby, D | 1 |
| Goedert, JJ | 1 |
| Yarchoan, R | 1 |
| Lowell, B | 1 |
| Getty, J | 1 |
| Grunfeld, C | 1 |
| James, JS | 3 |
| Barr, D | 1 |
| Gilden, D | 3 |
| Cooper, S | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Fieldston, E | 1 |
| Mathé, G | 1 |
| Higgins, SP | 1 |
| Bradbeer, CS | 1 |
| Georghiou, PR | 1 |
| Allworth, AM | 1 |
| Bouza, E | 1 |
| Muñoz, P | 1 |
| Diaz, MD | 1 |
| Vicente, T | 1 |
| Ryan, J | 1 |
| Colman, J | 1 |
| Pedersen, J | 1 |
| Williams, I | 1 |
| Weller, IV | 1 |
| Malni, A | 1 |
| Anderson, J | 1 |
| Waters, MF | 1 |
| Allegue, F | 1 |
| Sarriá Cepeda, C | 1 |
| García Rodríguez, M | 1 |
| Tercedor, J | 1 |
| Ortego, N | 1 |
| Ródenas, JM | 1 |
| Hernández, J | 1 |
| Gorin, I | 2 |
| Vilette, B | 1 |
| Gehanno, P | 2 |
| Escande, JP | 1 |
| Youle, M | 1 |
| Hawkins, D | 1 |
| Barry, B | 1 |
| Depondt, J | 1 |
| Guedon, C | 1 |
| Poignonec, S | 1 |
| Leport, C | 1 |
| Nicolau, DP | 1 |
| West, TE | 1 |
| Bernardo, P | 1 |
| Arrizabalaga, J | 1 |
| Iribarren, JA | 1 |
| Garde, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of a TNF-Alpha Modulator for the Treatment of Oral Lesions in HIV/AIDS Patients[NCT00001524] | Phase 2 | 110 participants | Interventional | 1996-06-30 | Completed | ||
| Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection[NCT00000790] | Phase 2 | 164 participants | Interventional | Completed | |||
| A Randomised, Double-blind, Placebo-controlled Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding[NCT02754960] | Phase 2 | 0 participants (Actual) | Interventional | 2010-03-31 | Withdrawn | ||
| Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study[NCT00964496] | Phase 2 | 55 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| A PHASE II STUDY OF ORAL THALIDOMIDE FOR PATIENTS WITH HIV INFECTION AND KAPOSI'S SARCOMA[NCT00019123] | Phase 2 | 0 participants | Interventional | 1996-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 13 |
| Iron-controlled Group | 0 |
The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | days (Mean) |
|---|---|
| Thalidomide Group | 5.2 |
| Iron-controlled Group | 0.8 |
The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | bleeding episodes (Mean) |
|---|---|
| Thalidomide Group | -9.36 |
| Iron-controlled Group | 1.41 |
The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | g/L (Mean) |
|---|---|
| Thalidomide Group | 3.06 |
| Iron-controlled Group | -0.01 |
Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | milliliter (Mean) |
|---|---|
| Thalidomide Group | -1585.71 |
| Iron-controlled Group | -28.57 |
Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 3 |
| Iron-controlled Group | 13 |
The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 20 |
| Iron-controlled Group | 1 |
5 reviews available for thalidomide and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
[Treatment of KSHV infection].
Topics: Acquired Immunodeficiency Syndrome; Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; | 2006 |
Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches.
Topics: Acetylcysteine; Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Body Comp | 1995 |
Thalidomide revisited.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Animals; Behcet Syndrome; Bone Marr | 1994 |
Thalidomide as an emerging immunotherapeutic agent.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Anti-Inflam | 1999 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
9 trials available for thalidomide and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Thalidomide effective for AIDS-related oral ulcers.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Esophageal Diseases; Humans; Placebos; Sto | 1995 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Double-Blind Method; Female; HIV-1; Humans; Male; Quality | 1997 |
Thalidomide: a novel therapy for microsporidiosis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Animals; Diarrhea; Female; Humans; Male; Microsporidiosis | 1997 |
Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antigens, CD; Double-Blind Method; Esophageal Diseases; E | 1999 |
Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Adult; Body Mass Index; CD40 Ligand; Cyt | 2000 |
Activity of thalidomide in AIDS-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Anti-HIV Agents; Disease Progressio | 2000 |
Thalidomide: new expanded access for wasting.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Costs and Cost Analysis; Female; Hotlines; Humans; Imm | 1995 |
Thalidomide's elusive access.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Randomized Controlle | 1995 |
Thalidomide and aphthous ulcers.
Topics: Acquired Immunodeficiency Syndrome; Humans; Placebos; Stomatitis, Aphthous; Thalidomide | 1995 |
46 other studies available for thalidomide and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretro | 2017 |
Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Coronary Angiography; Humans; Immune Reconstitution Infla | 2015 |
Lenalidomide in treating AIDS-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; HIV-1; Humans; Lenalidomide; Sarcoma, Kaposi; Skin Neoplasms; Th | 2011 |
Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiretroviral The | 2012 |
Risk versus risk: decision-making dilemmas of drug regulation in the United States and Germany.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Drug Approval; Drugs, | 2000 |
Finding new uses for thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Humans; Stomatitis, Aphthous; Thalidomide | 1995 |
Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide.
Topics: Acquired Immunodeficiency Syndrome; HIV Infections; Humans; Male; Middle Aged; Photosensitivity Diso | 1995 |
[Efficacy of thalidomide in the treatment of esophageal ulcers in human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Fatal Outcome; HIV Infections; HIV S | 1995 |
Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals.
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Female; HIV Seropositivity; HIV-1; H | 1995 |
Thalidomide inhibits the replication of human immunodeficiency virus type 1.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cell Line; Female; HIV Infections; HIV-1; Humans; Leukocy | 1993 |
Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; HIV-1; Humans; Male; Stomatitis, Aphthous; Thalid | 1993 |
Esophageal ulcers in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Esophageal Diseases; Humans; Thalidomide; Ulc | 1996 |
Esophageal ulcers in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-Ulcer Agents; Esophageal Diseases; Humans; Thalidomide; Ulc | 1996 |
Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV.
Topics: Acquired Immunodeficiency Syndrome; Adult; Endoscopy, Digestive System; Esophageal Diseases; Humans; | 1996 |
Thalidomide heals HIV-related oral ulcers, but caution is required.
Topics: Acquired Immunodeficiency Syndrome; Humans; Stomatitis, Aphthous; Thalidomide | 1997 |
Jekyll and Hyde: a new license for thalidomide?
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Antineoplastic Agents; Clinical Tri | 1997 |
Severe oral ulceration in patients with HIV infection: a case series.
Topics: Acquired Immunodeficiency Syndrome; Adult; Clinical Protocols; Decision Trees; Diagnosis, Differenti | 1997 |
Thalidomide heals AIDS-related mouth ulcers.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Humans; Oral Ulcer; Thalidomide | 1997 |
Steroid-resistant idiopathic esophageal ulcer in a child with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Candidiasis; Child, Preschool; Drug Resistance; Esophageal Disea | 1998 |
The problem with thalidomide's new incarnation.
Topics: Acquired Immunodeficiency Syndrome; Drug Approval; Humans; Leprosy; Neoplasms; Thalidomide; United S | 1998 |
Treatment of AIDS-associated prurigo nodularis with thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dermatologic Agents; Humans; Male; Prurigo; Thalidomide | 1998 |
Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Fatal Outcome; Humans; Immunosuppressive Agents; Male; Or | 2000 |
Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: clinical improvement after initiation of thalidomide treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Diagnosis, Differential; Granuloma, Plas | 2000 |
Thalidomide, the FDA, and us -- what do you have? Underground compassionate use. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Teratogens; Thalidom | 1995 |
Growing interest in thalidomide.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cells, Cultured; Clinical Trials as Topic; Female; Humans | 1995 |
Turning the corner on wasting? A symposium on wasting disorders.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cachexia; Endocrine System Diseases; Humans; M | 1995 |
State of the art in wasting: an interview with Carl Grunfeld, PhD. Interview by Jeff Getty.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Animals; Cachexia; Endocr | 1995 |
Wasting syndrome--affordable treatments.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Costs and Cost Analysis; Dronabinol; Exercise Therapy; | 1995 |
Expanded access for experimental AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Drug Approval; Drugs, Investigational; HIV Protease Inhibitors; | 1995 |
Treatment for weight loss, tuberculosis and AIDS?
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Stomatitis, Aphthous | 1995 |
Thalidomide for wasting syndrome: progress toward compromise.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cachexia; Dose-Response R | 1995 |
Thalidomide, gentrified.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Drug Costs; Female; Humans; Male; Stomatitis, Aphthous | 1996 |
AIDS, thalidomide and maternal-fetal rights in conflict.
Topics: Abortion, Eugenic; Acquired Immunodeficiency Syndrome; Coercion; Contraception; Drug-Related Side Ef | 1998 |
Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system.
Topics: Acquired Immunodeficiency Syndrome; Erythema Nodosum; Graft vs Host Reaction; Humans; Immunosuppress | 2002 |
Thalidomide: a restricted role.
Topics: Acquired Immunodeficiency Syndrome; Humans; Stomatitis, Aphthous; Thalidomide | 1992 |
Thalidomide in painful AIDS-associated proctitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Opportunistic Infections; Proctitis; Thalid | 1992 |
Thalidomide in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Mycobacterium avium-intracellulare Infectio | 1992 |
Thalidomide to treat esophageal ulcer in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Humans; Male; Thalidomide; Ulcer | 1992 |
Thalidomide hypersensitivity in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Drug Hypersensitivity; Humans; Male; Stomatitis, Aphthous; Thali | 1991 |
[Aphthosis major treated with thalidomide in a patient with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Immunosuppressive Agents; Male; Stomatitis, Aphth | 1991 |
[Treatment of recurrent aphthae with thalidomide in patients with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Male; Stomatitis, Aphthous; Thalidomide; Time Fac | 1991 |
Thalidomide in hyperalgic pharyngeal ulceration of AIDS.
Topics: Acquired Immunodeficiency Syndrome; HIV Seropositivity; Homosexuality; Humans; Male; Middle Aged; Ph | 1990 |
Thalidomide in hyperalgic pharyngeal ulceration of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Humans; Hyperalgesia; Hyperesthesia; Pharyngeal Diseases; Stomat | 1990 |
[Mouth and pharyngeal hyperalgesic syndromes in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Middle Aged; Mouth Diseases; Pain; | 1990 |
Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Recurrence; Stomatitis, Aphthous; T | 1990 |
[Effectiveness of thalidomide in non specific esophageal ulcer in patients with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Humans; Male; Thalidomide; Ulcer | 1990 |